NEW YORK (GenomeWeb News) – Myriad Genetics said this week that BioMarin Pharmaceutical will use its BRACAnalysis test in its pivotal Phase 3 clinical study for BMN 673, an orally active PARP-inhibitor designed to induce synthetic lethality in BRCA-deficient cells. Myriad has submitted an Investigational Device Exemption to the US Food and Drug Administration that would allow the BRACAnalysis test to be used as a companion diagnostic to stratify patients in the BMN 673 clinical program, as required by FDA.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.